Summary: Analysis of the results raised in the Framingham and the MRFIT study have clearly shown that increased pulse pressure is an independent cardiovascular risk factor. This is valid for all age groups and both sexes. The risk increases with pulse pressures over 60 - 65 mmHg for office blood pressure and 53 mmHg for 24-h-mean of ambulatory blood pressure. Pulse pressure is strongly correlated with systolic blood pressure and will be highest in case of isolated systolic hypertension. Urinary albumin excretion and left ventricular hypertrophy are closely associated with pulse pressure. With elevated pulse pressure cardiovascular risk is increased 2- to 4-fold in relation to age and endpoint. The risk of myocardial infarction is raised more if pulse pressure is associated with low mean arterial blood pressure while risk of stroke is increased with wide pulse pressure and high mean arterial pressure. The risk of pulse pressure can be seen in normotensives and in early pregnancy. Therapeutic management of pulse pressure will be similar to that of systolic blood pressure, since normalization of systolic blood pressure will also lower or normalize pulse pressure. Results of preliminary studies suggest that diuretics are superior to other drugs in decreasing pulse pressure. An increase of pulse pressure during therapy should be avoided since each 10 mmHg increase in pulse pressure will raise the risk of stroke and myocardial infarction about 24 % and 32 %.
Literatur
-
1
Cushman W C, Materson B J, Williams D W. et al .
Pulse pressure
changes with six classes of antihypertensive agents in a randomized,
controlled trial.
Hypertension.
2001;
38
953-957
-
2
Domanski M J, Davis B R, Pfeffer M A. et al .
Isolated systolic hypertension. Prognostic
Information Provided by Pulse Pressure.
Hypertension.
1999;
34
375-380
-
3
Domanski M J, Mitchell G, Pfeffer M A. et al .
Pulse pressure and cardiovascular disease-related
mortality: follow-up study of the Multiple Risk Factor Intervention
Trial (MRFIT).
JAMA.
2002;
287
2677-2683
-
4
Domanski M J, Normann J, Wolz M. et al .
Cardiovascular risk assessment using pulse
pressure in the first national health and nutrition examination
survey (NHANES I).
Hypertension.
2001;
38
793-797
-
5
Fagard R H, Pardaens K, Staessen J A. et al .
The pulse pressure-to-stroke index ratio
predicts cardiovascular events and death in uncomplicated hypertension.
J
Am Coll Cardiol.
2001;
38
227-231
-
6
Fang J, Madhavan S, Alderman M H.
Pulse
pressure: a predictor of cardiovascular mortality among young normotensive
subjects.
Blood pressure.
2000;
9
260-266
-
7
Gerdts E, Papademetriou V, Palmieri V. et al .
Correlates of pulse pressure reduction
during antihypertensive treatment (losartan or atenolol) in hypertensive
patients with electrocardiographic left ventricular hypertrophy
(the LIFE study).
Am J Cardiol.
2002;
89
399-402
-
8
Jokiniitty J M, Majahalme S K, Kähönen M A. et al .
Pulse pressure
is the best predictor of future left ventricular mass and change
in left ventricular mass: 10 years of follow-up.
J Hypertens.
2001;
19
2047-2054
-
9
Klassen P S, Lowrie E G, Reddan D N. et al .
Association between pulse
pressure and mortality in patients undergoing maintenance hemodialysis.
JAMA.
2002;
287
1548-1555
-
10
Millar J A, Lever A F, Burke V.
Pulse
pressure as a risk factor for cardiovascular events in the MRC Mild
Hypertension Trial.
J Hypertens.
1999;
17
1065-1072
-
11
Ohkubo T, Hozawa A, Imai Y.
Prognostic
impact of 24-hour mean blood pressure and pulse pressure on stroke.
Circulation.
2001;
104
E160
-
12
O‘Rourke M, Frohlich E D.
Pulse Pressure:
Is this a clinically useful risk factor?.
Hypertension.
1999;
34
372-374
-
13
Pedrinelli R, Dell’Omo G, Penno G. et al .
Microalbuminuria and pulse pressure in
hypertensive and atherosclerotic men.
Hypertension.
2000;
35
48-54
-
14
Safar M E, Levy B I, Laurent S. et al .
Hypertension and the arterial system: clinical
and therapeutic aspects.
J Hypertens.
1990;
8
S113-S119
(suppl 7)
-
15
SHEP Cooperative Research
Group .
Prevention of stroke by antihypertensive drug
treatment in older persons with isolated systolic hypertension. Final
results of the Systolic Hypertension in the Elderly Program (SHEP).
JAMA.
1991;
265
3255-3264
-
16
Staessen J A, Fagaro R, Thijs L. et al .
Randomised double-blind comparison of placebo
and active treatment for older patients with isolated systolic hypertension.
Lancet.
1997;
350
757-764
-
17
Thadhani R, Ecker J L, Kettyle E. et al .
Pulse pressure and risk of preeclampsia:
a prospective study.
Obstetrics and gynecology.
2001;
97
515-520
-
18
Vaccarino V, Berger A K, Abramson J. et al .
Pulse pressure and risk of cardiovascular
events in the systolic hypertension in the elderly program.
Am J
Cardiol.
2001;
88
980-986
-
19
Vasan R S, Larson M G, Leip E P. et al .
Impact of high-normal blood
pressure on the risk of cardiovascular disease.
N Engl
J Med.
2001;
345
1291-1297
-
20
Vasan R S, Massaro J M, Wilson P WF. et al .
Antecendent blood pressure
and risk of cardiovascular disease. The Framingham Heart Study.
Circulation.
2002;
105
48-53
-
21
Verdecchia P, Schillaci G, Borgioni C. et al .
Ambulatory pulse pressure. A potent predictor
of total cardiovascular risk in hypertension.
Hypertension.
1998;
32
983-988
-
22
Zanchetti A, Bond M G, Hennig M. et al .
Risk factors associated with alterations
in carotid intima-media thickness in hypertension: baseline data from
the European Lacidipine Study on Atherosclerosis.
J Hypertens.
1998;
16
949-961
-
23
Deutsche Liga zur Bekämpfung
des hohen Blutdruckes, deutsche Hypertoniegesellschaft .
Leitlinien
für die Prävention, Erkennung, Diagnostik und
Therapie der arteriellen Hypertonie.
Dtsch Med Wochenschr.
2001;
126
(Suppl 4)
Prof. Dr. Gerd Bönner
Klinik für Innere Medizin, MEDIAN-Klinikum
für Akut- und Rehabilitationsmedizin
Herbert-Hellmann-Allee
38
79189 Bad Krozingen
eMail: gerd.boenner@dgn.de
